Where Clinical Need Meets Innovation: A £500K Step Toward Safer Cardiac    Surgery

A Pivotal Step in Advancing PerDeCT 

Fallouh Healthcare was awarded a £500,000 grant from Innovate UK, the UK’s national innovation agency, to develop— PerDeCT,  

This award marked a transformative moment in our journey, helping us move from concept to prototype and proving that real-world surgical challenges can inspire real-world solutions. 

 Built Through Collaboration 

Delivered in partnership with: 

  • University Hospitals Birmingham NHS Foundation Trust 
  • The University of Sheffield 

The project combined clinical insight and academic research to build a solution that reflects the real needs of frontline healthcare teams.

Why It Matters: Reimagining Cardiac Tamponade Diagnosis 

Cardiac tamponade is a life-threatening complication that’s difficult to detect early with conventional tools. PerDeCT changes the equation — offering a quick, simple, and reliable way to identify fluid build-up around the heart before symptoms become critical

PerDeCT is: 

  • Non-invasive and easy to use at the bedside 
  • Designed for high-pressure environments like ICU and post-op wards 
  • Built with input from clinicians who understand what’s at stake 

What the Grant Enabled 

  • Prototype Development 

Built and refined our first-generation PerDeCT device, aligned to real clinical performance needs. 

  •  Human-Centred Design 

Collaborated with surgeons and ICU clinicians to ensure usability in demanding surgical environments. 

  • Usability Testing at MD-TEC 

Conducted hands-on evaluations at Queen Elizabeth Hospital (Medical Device Testing & Evaluation Centre), one of the UK’s top medtech testing hubs. 

  • Regulatory Roadmap 

Laid the foundations for CE marking and future clinical trials by initiating a regulatory strategy. 

Outcomes and Impact 

This Innovate UK project was more than product development — it validated our clinical relevance, engaged key NHS stakeholders, and paved the way for future investment and trials. It directly contributed to our success in securing follow-on funding, including our Eurostars award for preclinical studies. 

This grant affirmed our belief: ”when innovation starts with the clinician, the result is a device the whole system can trust”. CEO Hazem Fallouh 

Scroll to Top